SCHEMBL15566652

SCHEMBL15566652

CSc1ncc2c(C(F)F)ncc(I)c2n1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HASPIN Q8TF76 2/20 0.33
PIM1 P11309 1/20 0.30
TTK P33981 1/20 0.30
PIM2 Q9P1W9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24311814 0.83 HASPIN (0.34) HASPINPIM1TTKPIM2
SCHEMBL15566093 0.76 HASPIN (0.41) HASPINPIM1TTKPIM2
SCHEMBL29897656 0.76 HASPIN (0.41) HASPINPIM1TTKPIM2
SCHEMBL15565804 0.76 MEN1 (0.38) HASPIN
SCHEMBL15564739 0.71 MEN1 (0.35) HASPIN
SCHEMBL24340010 0.68 KDM4E (0.33) HASPIN
SCHEMBL20641990 0.67 LRRK2 (0.33) HASPIN
SCHEMBL30498457 0.67 HASPIN (0.44) HASPINPIM1TTKPIM2
SCHEMBL15565906 0.67 HASPIN (0.44) HASPINPIM1TTKPIM2
SCHEMBL29421498 0.67 MEN1 (0.40) HASPINPIM1TTKPIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022079250-A1 COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS MERCK PATENT GMBH (DE) 2022-04-21 WO disclosed
WO-2022079250-A1 COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS MERCK PATENT GMBH (DE) 2022-04-21 WO disclosed
US-9725462-B2 Pyridopyrimidine derivatives as protein kinase inhibitors MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
US-9725462-B2 Pyridopyrimidine derivatives as protein kinase inhibitors MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
US-9725462-B2 Pyridopyrimidine derivatives as protein kinase inhibitors MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
EP-2882746-B1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-12-07 EP disclosed
EP-2882746-B1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-12-07 EP disclosed
US-20150218186-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-08-06 US disclosed
US-20150218186-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-08-06 US disclosed
US-20150218186-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-08-06 US disclosed
EP-2882746-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Merck Patent GmbH (DE) 2015-06-17 EP disclosed
WO-2014023385-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-02-13 WO disclosed
WO-2014023385-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218186-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS SYK, LYN, IRAK1 HASPIN 1212/4885PIM1 402/4885TTK 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.